Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis

Published:2018-03-19 Issue:8 Volume:36 Page:1285-1297
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Chen Hsiao-Ling,Chen Tun-Chieh,Chang Hsiu-Mei,Juan Yung-Shun,Huang Wei-Hsuan,Pan Hung-Fang,Chang Yong-Chieh,Wu Chiou-Mei,Wang Ya-Ling,Lee Hsiang Ying^ORCID

Funder

Kaohsiung Municipal Ta-Tung Hospital

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/article/10.1007/s00345-018-2268-9/fulltext.html

Reference23 articles.

1. Chuang YC, Liu SP, Lee KS et al (2017) Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study. Low Urin Tract Symptoms 1–8. https://doi.org/10.1111/luts.12193

2. Milsom I, Coyne KS, Nicholson S et al (2014) Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol 65:79–95

3. Apostolidis A (2015) Antimuscarinics in the treatment of OAB: is there a first-line and a second-line choice? Curr Drug Targets 16:1187–1197

4. Kinjo M, Sekiguchi Y, Yoshimura Y et al (2016) Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial. Low Urin Tract Symptoms 1–5. https://doi.org/10.1111/luts.12151

5. Callegari E, Malhotra B, Bungay PJ et al (2011) A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72(2):235–246

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing Impact of Overactive Bladder Therapies on Nocturia;Urogynecology;2024-03

2. Flat Magnetic Stimulation for Urge Urinary Incontinence;Medicina;2023-11-14

3. Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women;Scientific Reports;2023-11-08

4. Clinical pharmacology of β-3 adrenergic receptor agonists for cardiovascular diseases;Expert Review of Clinical Pharmacology;2023-09-20

5. Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice;Pharmaceutics;2023-09-04